Ardelyx vs Travere Therapeutics
ARDX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and TVTX compare
Travere Therapeutics is the larger company, worth 6.2 times as much as Ardelyx ($4.8B against $770M).
Travere Therapeutics grew revenue faster over the last twelve months (49.4% versus 16.8% for Ardelyx).
Ardelyx keeps more of each dollar of sales as profit, with a net margin of −12.4% compared with −18.7% at Travere Therapeutics.
Ardelyx scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $770M | $4.8B |
| Share price | $3.09 | $50.65 |
| Change, 1 year | −48.8% | 38.9% |
| Change, 5 years | 209% | 73.0% |
| Beta (5Y) | 0.95 | 1.14 |
| Employees | 489 | 497 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.7× (better) | 7.3× |
| P/B | 5.2× (better) | 211× |
| FCF yield | −2.3% | – |
| Fair value | $7.50 | – |
| Margin of safety | 58.8% | – |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 49.4% (better) |
| Revenue growth, 5Y average | 122% (better) | 19.9% |
| Profitability | ||
| Gross margin | 94.4% | 98.5% (better) |
| Operating margin | −7.9% (better) | −20.5% |
| Net margin | −12.4% (better) | −18.7% |
| FCF margin | −4.0% | – |
| Return on equity | −38.6% (better) | −253% |
| Financial health | ||
| Interest coverage | −1.6× (better) | −15.1× |
| Current ratio | 3.34 (better) | 3.00 |
| Altman Z-score | −0.13 | 1.68 (better) |
| Piotroski F-score | 3 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.2% | 112% |
| Held by insiders | 6.9% | 1.6% |
| Insider net buying, 12 months | −$1.9M (better) | −$110M |
| Short interest, % of float | 12.6% | 10.3% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.